Annual Total Long Term Liabilities
$361.79 M
-$66.54 M-15.54%
31 December 2023
Summary:
Standard BioTools annual total long term liabilities is currently $361.79 million, with the most recent change of -$66.54 million (-15.54%) on 31 December 2023. During the last 3 years, it has risen by +$230.74 million (+176.07%). LAB annual total long term liabilities is now -15.54% below its all-time high of $428.33 million, reached on 31 December 2022.LAB Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$71.59 M
-$3.07 M-4.11%
30 September 2024
Summary:
Standard BioTools quarterly total long term liabilities is currently $71.59 million, with the most recent change of -$3.07 million (-4.11%) on 30 September 2024. Over the past year, it has dropped by -$290.20 million (-80.21%). LAB quarterly long term liabilities is now -83.57% below its all-time high of $435.81 million, reached on 30 June 2022.LAB Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LAB Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -80.2% |
| 3 y3 years | +176.1% | -45.4% |
| 5 y5 years | +361.6% | -8.7% |
LAB Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -15.5% | +176.1% | -83.6% | at low |
| 5 y | 5 years | -15.5% | +361.6% | -83.6% | at low |
| alltime | all time | -15.5% | >+9999.0% | -83.6% | +6884.5% |
Standard BioTools Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $71.59 M(-4.1%) |
| June 2024 | - | $74.66 M(-5.2%) |
| Mar 2024 | - | $78.80 M(-78.2%) |
| Dec 2023 | $361.79 M(-15.5%) | $361.79 M(-13.7%) |
| Sept 2023 | - | $419.20 M(-0.8%) |
| June 2023 | - | $422.37 M(-0.6%) |
| Mar 2023 | - | $425.02 M(-0.8%) |
| Dec 2022 | $428.33 M(+226.8%) | $428.33 M(-0.7%) |
| Sept 2022 | - | $431.49 M(-1.0%) |
| June 2022 | - | $435.81 M(+115.1%) |
| Mar 2022 | - | $202.65 M(+54.6%) |
| Dec 2021 | $131.05 M(-0.3%) | $131.05 M(-3.3%) |
| Sept 2021 | - | $135.56 M(+6.7%) |
| June 2021 | - | $127.02 M(-1.3%) |
| Mar 2021 | - | $128.73 M(-2.1%) |
| Dec 2020 | $131.46 M(+67.7%) | - |
| Dec 2020 | - | $131.46 M(+2.5%) |
| Sept 2020 | - | $128.21 M(+15.2%) |
| June 2020 | - | $111.28 M(-1.8%) |
| Mar 2020 | - | $113.36 M(+44.6%) |
| Dec 2019 | $78.38 M(-59.6%) | - |
| Dec 2019 | - | $78.38 M(+6.7%) |
| Sept 2019 | - | $73.42 M(-0.6%) |
| June 2019 | - | $73.83 M(-1.6%) |
| Mar 2019 | - | $75.02 M(-61.3%) |
| Dec 2018 | $193.95 M(-13.0%) | $193.95 M(+1.5%) |
| Sept 2018 | - | $191.01 M(+1.8%) |
| June 2018 | - | $187.62 M(+0.1%) |
| Mar 2018 | - | $187.42 M(-15.9%) |
| Dec 2017 | $222.94 M | $222.94 M(+0.9%) |
| Sept 2017 | - | $221.04 M(+0.3%) |
| June 2017 | - | $220.45 M(-1.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2017 | - | $222.68 M(-0.4%) |
| Dec 2016 | $223.66 M(-0.6%) | $223.66 M(-0.4%) |
| Sept 2016 | - | $224.53 M(-0.4%) |
| June 2016 | - | $225.46 M(+0.2%) |
| Mar 2016 | - | $224.94 M(-0.1%) |
| Dec 2015 | $225.07 M(-1.2%) | $225.07 M(-0.8%) |
| Sept 2015 | - | $226.88 M(-0.0%) |
| June 2015 | - | $226.98 M(-0.3%) |
| Mar 2015 | - | $227.67 M(-0.0%) |
| Dec 2014 | $227.75 M(+8831.6%) | $227.75 M(-0.3%) |
| Sept 2014 | - | $228.53 M(-0.0%) |
| June 2014 | - | $228.61 M(-1.3%) |
| Mar 2014 | - | $231.56 M(+8980.6%) |
| Dec 2013 | $2.55 M(+72.5%) | $2.55 M(+16.7%) |
| Sept 2013 | - | $2.19 M(+11.9%) |
| June 2013 | - | $1.95 M(+24.0%) |
| Mar 2013 | - | $1.58 M(+6.6%) |
| Dec 2012 | $1.48 M(-34.5%) | $1.48 M(+12.7%) |
| Sept 2012 | - | $1.31 M(+5.2%) |
| June 2012 | - | $1.25 M(+21.6%) |
| Mar 2012 | - | $1.02 M(-54.6%) |
| Dec 2011 | $2.26 M(-98.8%) | $2.26 M(-40.4%) |
| Sept 2011 | - | $3.79 M(-32.2%) |
| June 2011 | - | $5.59 M(-24.5%) |
| Mar 2011 | - | $7.41 M(-96.2%) |
| Dec 2010 | $195.46 M(-1.6%) | $195.46 M(+1515.9%) |
| Sept 2010 | - | $12.10 M(-93.9%) |
| Dec 2009 | $198.64 M(+9.0%) | $198.64 M(+9.0%) |
| Dec 2008 | $182.17 M(+5.0%) | $182.17 M(+1.9%) |
| June 2008 | - | $178.84 M(+3.1%) |
| Dec 2007 | $173.53 M(+28.1%) | $173.53 M |
| Dec 2006 | $135.51 M | - |
FAQ
- What is Standard BioTools annual total long term liabilities?
- What is the all time high annual total long term liabilities for Standard BioTools?
- What is Standard BioTools quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Standard BioTools?
- What is Standard BioTools quarterly long term liabilities year-on-year change?
What is Standard BioTools annual total long term liabilities?
The current annual total long term liabilities of LAB is $361.79 M
What is the all time high annual total long term liabilities for Standard BioTools?
Standard BioTools all-time high annual total long term liabilities is $428.33 M
What is Standard BioTools quarterly total long term liabilities?
The current quarterly long term liabilities of LAB is $71.59 M
What is the all time high quarterly long term liabilities for Standard BioTools?
Standard BioTools all-time high quarterly total long term liabilities is $435.81 M
What is Standard BioTools quarterly long term liabilities year-on-year change?
Over the past year, LAB quarterly total long term liabilities has changed by -$290.20 M (-80.21%)